SUSQUEHANNA INTERNATIONAL GROUP, LLP - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 101 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.

Quarter-by-quarter ownership
SUSQUEHANNA INTERNATIONAL GROUP, LLP ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$17,110
-70.5%
14,500
-64.8%
0.00%
Q2 2023$58,065
-95.3%
41,181
-95.0%
0.00%
Q1 2023$1,224,581
+502.8%
816,387
+370.2%
0.00%
Q4 2022$203,134
+120.8%
173,619
+113.8%
0.00%
Q3 2022$92,000
-66.2%
81,200
-52.9%
0.00%
Q2 2022$272,000
-13.4%
172,400
-15.7%
0.00%
Q1 2022$314,000
-87.1%
204,400
-79.5%
0.00%
Q4 2021$2,442,000
+33.7%
996,860
+37.6%
0.00%
Q3 2021$1,826,000
+114.1%
724,501
+142.0%
0.00%
Q2 2021$853,000
-68.0%
299,319
-73.6%
0.00%
Q1 2021$2,665,000
+24.6%
1,134,482
-6.6%
0.00%
Q4 2020$2,138,000
+4759.1%
1,214,286
+2494.6%
0.00%
Q3 2020$44,000
+25.7%
46,800
+15.8%
0.00%
Q2 2020$35,000
-56.2%
40,400
-58.1%
0.00%
Q1 2020$80,000
+50.9%
96,381
+62.6%
0.00%
Q4 2019$53,000
-44.2%
59,291
-39.4%
0.00%
Q3 2019$95,00097,8200.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q2 2022
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,005,379$83,313,0005.12%
Defender Capital, LLC. 4,997,870$12,245,0003.92%
Raffles Associates 543,590$1,332,0001.28%
Prescott General Partners LLC 1,851,851$4,537,0000.16%
DCF Advisers, LLC 85,000$208,0000.08%
Long Focus Capital Management, LLC 215,000$527,0000.07%
Beirne Wealth Consulting Services, LLC 45,000$110,0000.06%
DAFNA Capital Management LLC 80,000$196,0000.05%
Strategic Wealth Investment Group, LLC 65,069$159,0000.04%
Fort Sheridan Advisors LLC 52,931$130,0000.04%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders